February

February 27, 2015

Regulation of NFKB signalling: Neurotensin suppresses the expression of TNFAIP3, the negative regulator of NFKB, via down regulation of its target gene, 27/February/2015, 23.22

Idea Proposed/Formulated by: Dr L Boominathan Ph.D. Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/ Citation: Boominathan, Regulation of NFKB signalling: Neurotensin  suppresses the expression of TNFAIP3, the negative regulator of NFKB, via […]
February 27, 2015

MiRNA-based anti-tumor immunity enhancement therapy: MiRNA-128-2 promotes anti-tumor immunity via down regulation of its target gene, 27/February/2015, 23.02

Idea Proposed/Formulated by: Dr L Boominathan Ph.D. Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/ Citation: Boominathan, MiRNA-based anti-tumor immunity enhancement therapy: MiRNA-128-2 promotes anti-tumor immunity via down regulation of its target gene, […]
February 27, 2015

MiRNA-based therapy for Melonama: MiRNA-203 increases the expression of ADAR1 and inhibits melanoma progression via down regulation of its target gene, 27/February/2015, 09.10 am

Idea Proposed/Formulated by: Dr L Boominathan Ph.D. Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/ Citation: Boominathan, MiRNA-based therapy for Melonama:  MiRNA-203 increases the expression of ADAR1 and inhibits melanoma progression via down […]
February 27, 2015

Molecular therapy for cancer: Tumor suppressor p53 increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation in cancer via down regulation of its target gene, 27/February/2015, 9.07 am

A recent study from the Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy shows that “PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer.” This study was published […]